GlassScriptPhysician profile
Susan L Rusnack
NPI 1790957504
$5,596.36
in general payments reported to CMS, 2019-2025
38 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $120 · 2021: $605 · 2022: $630 · 2023: $1,377 · 2024: $1,070 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414 · Education: $185 · Travel and Lodging: $64.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.97 |
| Education | $184.98 |
| Travel and Lodging | $64.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,126.27 | 2021-2025 | Botox, Lupron Depot |
| Bluewind Medical | $513.45 | 2024-2025 | Revi |
| Axonics, INC. | $427.43 | 2022-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $387.85 | 2019-2025 | Xtandi |
| Pfizer INC. | $381.54 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $300.76 | 2023-2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $216.74 | 2019-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $213.67 | 2020-2025 | Adstiladrin |
| Allergan, INC. | $204.53 | 2019-2021 | |
| Urogen Pharma, INC. | $183.46 | 2023 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $131.84 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $120.35 | 2021-2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $119.96 | 2021-2025 | Erleada |
| Telix Pharmaceuticals | $118.36 | 2024-2025 | Illuccix |
| Therapeuticsmd, INC. | $111.35 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $106.99 | 2019-2021 | |
| Profound Medical Corp. | $88.19 | 2023 | Tulsa-Pro |
| Myovant Sciences INC. | $80.92 | 2022 | |
| Medtronic, INC. | $76.50 | 2023-2025 | Interstim |
| Blue Earth Diagnostics | $70.04 | 2021-2023 | |
| Calyxo, INC. | $55.19 | 2025 | Cvac Aspiration System |
| Abc Home Medical Supply, INC. | $54.19 | 2023-2025 | |
| Teleflex LLC | $51.46 | 2024 | Solesta |
| Amgen INC. | $49.40 | 2019 | |
| Coloplast Corp | $47.42 | 2021 | |
| Myriad Genetic Laboratories, INC. | $46.96 | 2021-2023 | Prolaris |
| Immunitybio, INC. | $46.06 | 2025 | |
| Laborie Medical Technologies Corp. | $43.06 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Duchesnay USA Incorporated | $42.86 | 2019 | |
| Ethicon US, LLC | $25.78 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.80 | 2019 | |
| Agile Therapeutics, INC. | $24.34 | 2021 | |
| Urovant Sciences INC | $20.28 | 2022 | |
| Travere Therapeutics, INC. | $18.03 | 2019 | |
| Hollister Incorporated | $17.30 | 2024 | Vapro |
| Progenics Pharmaceuticals, INC. | $17.07 | 2021 | |
| Tolmar, INC. | $16.96 | 2023 | |
| Glaxosmithkline, LLC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Rusnack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.